II. Indications

  1. Ventricular Arrhythmia
  2. Atrial Fibrillation Cardioversion (or Atrial Flutter)
    1. Time to Cardioversion: 3-6 hours
    2. Conversion Rate: 20-52%
    3. Chronic Efficacy: 50-60%

III. Mechanism

  1. Class III Antiarrhythmic
    1. Prolongs Action Potential duration
    2. Prolongs cardiac tissue refractory period throughout heart Muscle
  2. Class II Antiarrhythmic
    1. Non-selective Beta Blocker

IV. Precautions

  1. Proarrhythmic with risk of Torsades de Pointes
  2. Initiate in monitored setting capable of cardiac Resuscitation
  3. Monitoring
    1. Telemetry
    2. Renal Function (GFR)

V. Dosing

  1. Precautions
    1. Different formulations (Betapace, Betapace AF and Sotylize solution) are NOT equivalent
    2. Adjust dose in Renal Insufficiency
  2. Ventricular Arrhythmia (Betapace, Sotylize)
    1. Start 80 mg orally twice daily
    2. Target: 80-160 mg orally twice daily
    3. Maximum: 640 mg per day (Betapace), 320 mg/day (Sotylize)
  3. Atrial Fibrillation Rhythm Control (Betapace AF, Sotylize)
    1. Start 80 mg orally twice daily
    2. Target: 80-160 mg orally twice daily
    3. Maximum: 640 mg per day (Betapace AF), 160 mg/day (Sotylize)

VI. Adverse Effects

  1. Hypotension
  2. Torsades de Pointes
    1. Associated with doses over 320 mg per day
    2. Higher risk in Congestive Heart Failure and female gender

VII. Safety

  1. Pregnancy Category B
  2. Avoid in Lactation

IX. References

  1. Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 78-9
  2. Hamilton (2020) Tarascon Pocket Pharmacopoeia

Images: Related links to external sites (from Bing)

Related Studies

Cost: Medications

sotalol (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing)
SOTALOL 120 MG TABLET Generic $0.10 each
SOTALOL 160 MG TABLET Generic $0.16 each
SOTALOL 80 MG TABLET Generic $0.08 each
SOTALOL AF 120 MG TABLET Generic $0.10 each
SOTALOL AF 160 MG TABLET Generic $0.16 each
SOTALOL AF 80 MG TABLET Generic $0.08 each

Ontology: Sotalol (C0037707)

Definition (NCI) An ethanolamine derivative with Class III antiarrhythmic and antihypertensive properties. Sotalol is a nonselective beta-adrenergic receptor and potassium channel antagonist. In the heart, this agent inhibits chronotropic and inotropic effects thereby slowing the heart rate and decreasing myocardial contractility. This agent also reduces sinus rate, slows conduction in the atria and in the atrioventricular (AV) node and increases the functional refractory period of the AV node.
Definition (MSH) An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH D013015
SnomedCT 372911006, 96301002
LNC LP16279-9, MTHU003385
English Sotalol, Methanesulfonamide, N-(4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)phenyl)-, sotalol, Sotalol [Chemical/Ingredient], antiarrhythmics sotalol, sotalol (medication), SOTALOL, Sotalol (product), Sotalol (substance)
Swedish Sotalol
Czech sotalol
Finnish Sotaloli
Russian SOTALOL, СОТАЛОЛ
Japanese ソタロール
Polish Sotalol
Spanish sotalol (producto), sotalol (sustancia), sotalol, Sotalol
French Sotalol
German Sotalol
Italian Sotalolo
Portuguese Sotalol

Ontology: Betapace (C0728751)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
English Betapace, betapace